News and Trends 15 Nov 2017 Swiss Biotech Rakes in Biggest Fundraising of 2017 to Regenerate Heart Valves Xeltis has raised a €45M Series C to boost the development of its pioneering medical device, RestoreX, which helps to replace damaged heart valves. Xeltis, based in Zurich, Switzerland, is a clinical-stage medical device company developing heart valves and blood vessels to allow the body to naturally restore heart valve function. The biotech has achieved a €45M […] November 15, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 9 Nov 2017 Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease Neurimmune and Ono Pharmaceutical have partnered to develop an antibody drug against a still undisclosed neurodegenerative disease. Neurimmune has a new partner to help it develop treatments for neurodegenerative diseases. Ono Pharmaceutical will work together with the Swiss biotech to develop human antibodies against a new disease target that remains undisclosed for now. In exchange for an […] November 9, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 Swiss Biotech Pulls Major Investors into €42M Series B for Cancer Vaccines NousCom is developing semi-personalized medicine that convinced investors like Abingworth to go in big for its off-the-shelf neoantigen vaccines. Based in Basel and run by a team of serial entrepreneurs with over 15 years of experience, NousCom is finding the middle ground between broadly applicable treatments and personalized medicine. “We are the only company working […] November 6, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II AC Immune’s Anti-Tau antibody for the treatment of Alzheimer’s disease has reached Phase II, prompting milestone payments from Genentech. Today, the first patient in a Phase II trial was dosed with AC Immune’s anti-Tau antibody for the treatment of Alzheimer’s disease. This triggered a milestone payment of CHF 14M (€12M) from its collaborator, Genentech, as part of an agreement […] November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 1 Nov 2017 Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in a post hoc analysis of Phase IIb data. GeNeuro’s stock rose by 30% on Monday following an announcement of promising results from its relapsing-remitting multiple sclerosis drug, GNbAC1. After six months, the highest dose demonstrated an anti-inflammatory effect and seemed to stimulate […] November 1, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 30 Oct 2017 Meet the Covagen Co-Founder that Closed Europe’s Biggest Acquisition in 2014 Dragan Grabulovski co-founded the biotech that became 2014’s largest acquisition in Europe. I caught up with him to hear about the journey and what happens to a founder after his or her company is acquired. Dragan Grabulovski was doing a PhD in pharmaceutical sciences at ETH Zurich in the group of Dario Neri when he […] October 30, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments ADC Therapeutics has received massive private funding to progress two of its lead candidates for cancer through clinical trials. ADC Therapeutics, based in Lausanne, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for the treatment of cancer. The technology uses the specificity of antibodies to deliver a therapeutic agent to target cells only. The biotech has […] October 23, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research. The Swiss firm BC Platforms has built a platform to facilitate access to and analysis of large volumes of genomic and clinical data. Since September, the company has been collaborating with Microsoft, […] October 16, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2017 Oral Drug to Treat Uterine Fibroids Boasts Phase III Success Myovant’s partner Takeda has reported Phase III results showing relugolix to be more effective in treating uterine fibroids than existing hormonal therapy. Myovant has announced positive results from its lead candidate, relugolix, which showed itself to be better than leuprorelin injections — a common first-line treatment — at reducing menstrual bleeding in a Phase III trial in patients […] October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 4 Oct 2017 4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […] October 4, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 27 Sep 2017 What’s this Top Swiss VC Up To These Days? General Partner Tells All Philip caught up with Markus Hosang to find out which companies the VC is keeping an eye on after its next round of fundraising. General Partner, Markus Hosang has a strong background in pharma and VC, which serves him well when searching through the bustling biotech industry in Europe. BioMed Partners is a very active […] September 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2017 Swiss-US Partners Reveal New Candidate for Autoimmune Disease Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […] September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email